Indications & Pipeline
Attillaps Holdings is building a portfolio of novel therapeutics targeting Demodex-driven inflammatory disease across ophthalmology, dermatology, and cutaneous autoimmune conditions. Our lead compound, GLK-321, is currently in active development with Glaukos Corporation.
Development Pipeline
From discovery to clinical development
across multiple indications.
Our pipeline reflects a systematic approach to building a portfolio of Demodex-targeted therapies — led by our out-licensed GLK-321 program in collaboration with Glaukos Corporation.
Our small molecule platform targets the root cause of Demodex-driven inflammatory disease.